logo

For the Inventor, By the Inventor

Rheinfelden, Switzerland

Tillotts Pharma Ag


USPTO Granted Patents = 33

% Expired Patents = 9.1



Trademarks = 4

Forward Citations = 625

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Thomas Buser (14 out of 18 patents)

silverMedal Roberto Carlos Bravo González (11 out of 15 patents)

bronzeMedal Felipe José Oliveira Varum (9 out of 9 patents)

4.  Esther Maria Furrer (7 out of 8 patents)

5.  Abdul Waseh Basit (7 out of 16 patents)

6.  Ana Cristina Freire (6 out of 6 patents)

7.  Roberto Carlos Bravo Gonzaléz (5 out of 5 patents)

8.  Felipe Varum (4 out of 4 patents)

9.  Tea Gunde (3 out of 27 patents)

10.  Sebastian Meyer (3 out of 18 patents)

11.  Felipe Jose Oliveira Varum (3 out of 3 patents)

12.  Brian K Evans (3 out of 7 patents)

13.  John Rhodes (3 out of 12 patents)

14.  Laetitia Von Rochow (3 out of 3 patents)

15.  Roberto Bravo (3 out of 3 patents)


Core Competencies:
Antibody Variants
Delayed Release
Modified Release
Coated Capsules
Inflammatory Bowel Disease
Orally Administrable
Aqueous Foamable
Solid Dosage Forms
Microgel Particles
Spheronization
Extrusion
Granulation

33 patents:

1. 12653786 - Preparation of solid dosage forms comprising antibodies by solutions/suspension layering (2026-06-16),
2. 12419843 - Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization (2025-09-23),
3. 12370147 - Coatable core for a modified release drug formulation (2025-07-29),
4. 12370146 - Method of producing a delayed release drug formulation (2025-07-29),
5. 12215146 - Antibody variants (2025-02-04),
6. 12209122 - Anti-TNF-alpha-antibodies and functional fragments thereof (2025-01-28),
7. 12043663 - Anti-TNF-alpha-antibodies and functional fragments thereof (2024-07-23),
8. 11999781 - Antibody variants (2024-06-04),
9. 11998641 - Modified release coated capsules (2024-06-04),
10. 11826470 - Preparation of solid dosage forms comprising antibodies by solution/suspension layering (2023-11-28),
11. 11717484 - Topical treatment of inflammatory bowel disease using antibodies and fragments thereof (2023-08-08),
12. 11534406 - Delayed release drug formulation (2022-12-27),
13. 11517534 - Delayed release drug formulation (2022-12-06),
14. 11472872 - Antibody variants (2022-10-18),
15. 11266605 - Modified release coated capsules (2022-03-08),
Company Overview
Tillotts Pharma AG is a Swiss pharmaceutical company specializing in the development and commercialization of innovative therapies for gastrointestinal diseases. The company focuses on addressing unmet medical needs through its research in areas such as inflammatory bowel disease and other digestive disorders. With a commitment to enhancing patient outcomes, Tillotts Pharma leverages its expertise in drug formulation and delivery, aiming to provide effective solutions in the global healthcare landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Tillotts Pharma Ag USPTO Patent Assignee Logo
33 Patents

#1 in Rheinfelden

#416 in Switzerland

#20,147 in the World

Rheinfelden, CH
Rheinfelden, Switzerland

Tillotts Pharma Ag

Forward Citations = 625

34 inventors:

goldMedal Thomas Buser (14 out of 18 patents)

silverMedal Roberto Carlos Bravo González (11 out of 15 patents)

bronzeMedal Felipe José Oliveira Varum (9 out of 9 patents)

4.  Esther Maria Furrer (7 out of 8 patents)

5.  Abdul Waseh Basit (7 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Tillotts Pharma Ag. Retrieved from https://idiyas.com/company/tillotts-pharma-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…